UroGen Pharma is performing safety and efficacy clinical trials in several urinary tract indications: UTUC and bladder cancer in leading centers in USA, Europe and Israel:

UTUC

OLYMPUS

The OLYMPUS study –  Optimized DeLivery of Mitomycin for Primary UTUC Study

A  Study Evaluating The Feasibility, Safety, Durability and Ablative Effect of MITOGEL™ (mitomycin) urothelial gel, 0.4% in Patients With Low Grade Upper Tract Urothelial Cancer.

Currently recruiting patients.

Read More

LOW GRADE BLADDER CANCER

OPTIMA

The OPTIMA study – OPTimized Instillation of Mitomycin for BlAdder Cancer Treament. A Prospective, Open Label, Comparative Dose Escalation Study Evaluating the Chemoablative Effect of  Intravesical Instillation of VESIGEL™ (mitomycin) urothelial gel, 0.18% in Patients with Non Muscle Invasive Bladder Cancer (NMIBC).

Study conducted in Europe and Israel. COMPLETED 

The OPTIMA study II – OPTimized Instillation of Mitomycin for BlAdder Cancer Treament. A Prospective, Open Label Study Evaluating the Chemoablative Effect of  Intravesical Instillation of VESIGEL™ (mitomycin) urothelial gel, 0.18% in Patients with Non Muscle Invasive Bladder Cancer (NMIBC).

Commencement of patient recruitment planned for H1 2018.

CARCINOMA IN SITU

VESIMUNE

Pilot, Open-label, phase II study, investigating the response to intravesical TMX‑101 VESIMUNE™ (imiquimod) in patients with CIS bladder cancer. Phase I study under IND.

COMPLETED

Contact

UroGen Pharma
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001